Sensorion Sas · EURONEXT:ALSEN
Sensorion Sas — Sensorion — J.P. Morgan Healthcare Conference 2026
38 slides from Sensorion Sas's conference presentation, January 2026
Slide 1: Unlocking The Potential Of Advanced Therapies For Hearing Loss
SENSORION Unlocking The Potential Of Advanced Therapies For Hearing Loss January 2026
Slide 2: Disclaimer
DISCLAIMER • This document has been prepared by Sensorion (the “Company”) and is provided for information • This document contains certain forward-looking statements. These statements are not guarantees purposes only. This document does not purport to contain comprehensive or complete information of
Slide 3: Establishing Global Leadership In Hearing Loss With Strong And Diversified Pipeline
Sensorion Establishing Global Leadership In Hearing Loss With Strong And Diversified Pipeline • Unmet clinical need: 1.5bn people affected by hearing loss (HL) • Multiple causes: genetic, environmental, idiopathic • Modality agnostic approach to hearing loss disorders • World-leading and exclusive p
Slide 4: Portfolio Of Advanced Hearing Loss Therapies
Sensorion Portfolio Of Advanced Hearing Loss Therapies Milestones Product Indication Discovery In-vivo POC Preclinical Phase 1 Phase 2 Phase 3 (estimated) 6-months follow-up SENS-501* Otoferlin Deficiency Phase 1/2 data in Q1 2026 for C2 GENE THERAPIES HL related to GJB2 mutations RESTORE SENS-601*
Slide 5: Best-In-Class Partners And Internal Capabilities To Transform Standard Of Care
Sensorion Best-In-Class Partners And Internal Capabilities To Transform Standard Of Care TRANSLATIONAL CLINICAL DIAGNOSIS AND RESEARCH RESEARCH PATIENT JOURNEY PARTNERS GLOBAL CLINICAL CENTERS OF EXCELLENCE IN-HOUSE PRECLINICAL - CMC GENE THERAPY PATIENT ACCESS SMALL MOLECULES & CLINICAL EXPERIENCE
Slide 6: Gene Therapy Programs
1 GENE THERAPY PROGRAMS 6
Slide 7: Gene Therapy Programs Target Rare Auditory Diseases
Sensorion Gene Therapy Programs Target Rare Auditory Diseases FIRST PROGRAMS RESULTING FROM THE INSTITUT PASTEUR COLLABORATION OTOFERLIN DEFICIENCY GJB2-RELATED HEARING LOSS We have identified three forms of hearing loss associated with GJB2 gene mutations: • Pediatric patients with mutations in OTO
Slide 8: Otoferlin Deficiency
2 OTOFERLIN DEFICIENCY 8
Slide 9: Raising The Bar With The SENS-501 Audiogene Study
SENS-501 Raising The Bar With The SENS-501 Audiogene Study We wanted to generate a compelling value story showing that SENS-501 treatment is able to: • Demonstrate by itself hearing restoration in toddlers • Enable infants to have normal language acquisition and development • Improve Patient Reporte
Slide 10: SENS-501 Phase 1/2 Audiogene Study
SENS-501 Phase 1/2 Audiogene Study Audiogene, a Phase 1/2 clinical trial in homogenous population of infants and toddlers, aged 6 to 31 months, naive of cochlear implants, to assess safety, tolerability, and efficacy of SENS-501 following unilateral injection into the cochlea DMC Dose escalation DMC
Slide 11: SENS-501 Audiogene Study Status
SENS-501 Audiogene Study Status • Successful completion of recruitment for the first two cohorts (n=6) in H2 2025 • Good safety to date at both doses: • Surgical administration procedure well tolerated DOSE • No dose-limiting toxicities, no Serious Adverse Events • Vestibular function and OAEs remai
Slide 12: SENS-501 Program Status
SENS-501 Program Status Data CTA Approval Recruitment Monitoring Six-months IND in Various 1st and 2nd Committee results Process Countries Cohort End of H2 Q1 2026 Completed 2025 Copyright by Sensorion - 2026 - All Rights Reserved 12
Slide 13: GJB2-Related Hearing Loss
3 GJB2-RELATED HEARING LOSS 13
Slide 14: Leveraging SENS-501 Program For SENS-601 Program Success
SENS-601 (GJB2-GT) Leveraging SENS-501 Program For SENS-601 Program Success SENS-501 Is Paving The Way For GJB2-GT SENS-501 SENS-601 Aiming To Develop Best-In Class And First-In Class Gene Therapy • AAV capsid selected for high-level of target cells specificity • GT product showing high level of tar
Slide 15: Connexin 26 Is Encoded By GJB2 Gene And Is Responsible For Tissue Homeostasis
SENS-601 (GJB2-GT) Connexin 26 Is Encoded By GJB2 Gene And Is Responsible For Tissue Homeostasis Mutations In The GJB2 gene Lead To Deafness GJB2 Expression In The Cochlea • Connexin 26 and Connexin 30 proteins are the dominating connexins in the cochlea; heteromeric or heterotypic hexamers forming
Slide 16: Lead Candidate Can Deliver Connexin 26 In The Appropriate Target Cells
SENS-601 (GJB2-GT) Lead Candidate Can Deliver Connexin 26 In The Appropriate Target Cells Correct Delivery Of Connexin 26 Using Lead Candidate Flag In Non-Human Primate Cochlea Cell Types Claudius Cells Deiters Cells Great Epithelial Ridge Cells Hensen Cells Inner Border Cells Inner Hair Cells Inner
Slide 17: Lead Candidate Demonstrates Adequate Safety and Biodistribution Profile
SENS-601 (GJB2-GT) Lead Candidate Demonstrates Adequate Safety and Biodistribution Profile - Including Long-Term Local Tolerability in Mice and NHP Acute toxicity in WT Mice - High Dose IV injection • Study performed in preparation of upcoming GLP-toxicity in mice after IV injection • SENS-601 does
Slide 18: Lead Candidate Prevents Hearing Loss In Relevant Mouse Model
T+7w - 1X SENS-601 (GJB2-GT) 100 ABR Threshold (dB SPL) Lead Candidate Prevents Hearing Loss In Relevant Mouse Model 80 60 Proof Of Concept In Mice with Progressive Hearing Loss Proof Of Concept In Mice with Congenital 40 Hearing Loss Example of One Mouse Injected After Hearing Onset T+7w - 1X 20 AB
Slide 19: SENS-601 (GJB2-GT) Program Status
SENS-601 (GJB2-GT) Program Status Complete Ongoing Ongoing Update on IND/CTA European Natural History Additional Enabling Studies Clinical Trial Natural History Study PoC Efficacy - Applications Study in Collaboration and Safety Data Finalize regulatory Q1 2026 OTOCONEX with Sonova ASGCT 2025 Intera
Slide 20: SENS-401 Programs
4 SENS-401 PROGRAMS Multiple Indications To Treat And Prevent Hearing Loss 20
Slide 21: SENS-401 A Unique First-in-Class Asset
SENS-401 A Unique First-in-Class Asset Three Key Indications for Treatment and Prevention of Sensorineural Hearing Loss SUDDEN SENSORINEURAL HEARING PRESERVATION AFTER CISPLATIN-INDUCED OTOTOXICITY HEARING LOSS COCHLEAR IMPLANTATION • SSNHL is a sudden onset of a significant hearing loss • Potentia
Slide 22: SENS-401 Clinical Studies Summary
SENS-401 Clinical Studies Summary AUDIBLE-S study on SSNHL patients completed with positive findings in a PhIIb subgroup: • Complete PTA recovery is achieved in 50% of the SENS-401 treated patients, versus 30% in placebo patients • Significant effect on PTA change over time in a large homogeneous su
Slide 23: Conclusion
Sensorion Conclusion • Developing hearing loss therapeutics to treat, prevent and restore hearing – an area of high unmet clinical need • Combining extensive internal capabilities with world-leading exclusive partnerships • Advancing a robust and diversified pipeline with multiple upcoming milestone
Slide 24: Thank You
THANK YOU E:contact@sensorion-pharma.com 24
Slide 25: Appendix
_ . © Sensorion Appendix
Slide 26: Hearing Loss
HEARING LOSS 26 26
Slide 27: Access And Clarity Are Mandatory For Optimal Outcomes
HEARING Access And Clarity Are Mandatory For Optimal Outcomes (Hz) (dB HL) O = Right ear threshold Normal X = Left ear threshold Slight th f p s Mild t Hearing aid fitting range* z v h g k m d b ch j n o sh Moderate i a ng r Adults* e u Moderately-severe Severe Children O > 2 years* X O X O O O X O
Slide 28: Gene Therapy Programs Back-Up
GENE THERAPY PROGRAMS BACK-UP 28
Slide 29: OTOF Gene Encodes Otoferlin, a Key Ca2+ Sensor Protein
SENS-501 OTOF Gene Encodes Otoferlin, a Key Ca2+ Sensor Protein Increase in Ca2+ SNARE Proteins VAMP Ca2+ Ca2+ Ca2+ Ca2+ Vesicle Ca2+-Channel Otoferlin Pre-synaptic membrane neurotransmitters release restricted SNARE interaction Otoferlin SNARE interaction SNARE-complex binding primed vesicle contai
Slide 30: SENS-501 Leads to Restoration of Efficient Sound Processing in Behavioural Test
SENS-501 Leads to Restoration of Efficient Sound Processing in Behavioural Test Behavior Test Based on Hearing Recovery Implemented in Mouse White noise pulse (2-20 kHz, 115 dB) Wild type Non-injected Otof ko/ko Restored Otof ko/ko Olivier et al. ASGCT 2023 Copyright by Sensorion - 2026 - All Rights
Slide 31: SENS-401 Programs Back-Up
SENS-401 PROGRAMS BACK-UP Multiple Indications To Treat And Prevent Hearing Loss 31
Slide 32: SENS-401: A Pipeline In A Product Mechanism Of Action
SENS-401: A Pipeline In A Product Mechanism Of Action Disrupted Ca2+ Calcineurin INSULT homeostasis Activation Neurodegenerative cascades: Excitotoxicity Neuro Inflammation • NFAT translocation: oxidative stress, survival, inflammation pathways • Cell death pathways: BAD, mPTP, AIF, caspases activat
Slide 33: SSNHL Sudden Sensorineural Hearing Loss
SSNHL Sudden Sensorineural Hearing Loss 33
Slide 34: SSNHL is a Severe Disease Affecting more than 200,000 Patients Per Year
Sudden Sensorineural Hearing Loss (SSNHL) is a Severe Disease Affecting more than 200,000 Patients Per Year WHAT IS SSNHL? The sudden onset of a significant hearing loss due to dysfunction of the cells of the cochlea and central auditory structures. Hearing loss develops over less than 72 hrs, heari
Slide 35: SENS-401 SSNHL Program: AUDIBLE-S Phase 2 Design
SSNHL SENS-401 SSNHL Program: AUDIBLE-S Phase 2 Design A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL 50 clinical sites globally 1 Primary endpoint +/- oral corticosteroids Audiometry 15 dB improvement vs. Placebo +/- oral corticosteroids 115 patients enrolled Timing Q1 2019 June
Slide 36: SENS-401 Plasmatic Exposure
SSNHL SENS-401 Plasmatic Exposure PLASMATIC CONCENTRATION (Pre-dose at Day 14 and Day 28) 140 120 100 80 Legend ng/mL SENS-401 High dose 60 SENS-401 Low dose Placebo 40 20 0 Copyright by Sensorion - 2026 - All Rights Reserved 36
Slide 37: SENS-401 Induces Complete PTA Recovery In 50% Of Patients
SSNHL SENS-401 Induces Complete PTA Recovery In 50% Of Patients COMPLETE PTA RECOVERY Complete PTA Placebo High Dose Low Dose 70 p=0.1452 * p=0.0230 recovery (n/n total) % patients with complete PTA 60 p=0.1230 p=0.2707 Day 28 9/28 12/23 13/26 50 Day 84 8/26 8/18 14/22 recovery 40 30 20 Legend SENS-
Slide 38: SENS-401 SSNHL Phase 2 Results Summary
SSNHL SENS-401 SSNHL Phase 2 Results Summary AUDIBLE-S SECONDARY ENDPOINT RESULTS • Complete PTA recovery is achieved in 50% of the SENS-401 treated patients • SENS-401 shows a clinically meaningful and statistically significant effect on PTA change (at least 10 dB) over time in a large homogeneous